［1］ BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ TUMEN D,HEUMANN P,GULOW K,et al.Pathogenesis and current treatment strategies of hepatocellular carcinoma［J］.Biomedicines,2022,10(12):3202.
［3］ SOLIMANDO AG,SUMMA S,VACCA A,et al.Cancer-associated angiogenesis:the endothelial cell as a checkpoint for immunological patrolling［J］.Cancers,2020,12(11):3380.
［4］ LEE YT,TAN YJ,OON CE.Molecular targeted therapy:treating cancer with specificity［J］.Eur J Pharmacol,2018,834:188-196.
［5］ ITOH Y.Discoidin domain receptors:microenvironment sensors that promote cellular migration and invasion［J］.Cell Adh Migr,2018,12(4):378-385.
［6］ ELKAMHAWY A,LU Q,NADA H,et al.The journey of DDR1 and DDR2 kinase inhibitors as rising stars in the fight against cancer［J］.Int J Mol Sci,2021,22:6535.
［7］ MEHTA V,CHANDER H,MUNSHI A.Complex roles of discoidin domain receptor tyrosine kinases in cancer［J］.Clin Transl Oncol,2021,23(8):1497-1510.
［8］ GONG H,XU HM,ZHANG DK.Focusing on discoidin domain receptors in premalignant and malignant liver diseases［J］.Front Oncol,2023,13:1123638.
［9］ HENRIET E,SALA M,ABOU HA,et al.Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer［J］.Cell Adh Migr,2018,12(4):363-377.
［10］ GAO Y,ZHOU J,LI J.Discoidin domain receptors orchestrate cancer progression:a focus on cancer therapies［J］.Cancer Sci,2021,112(3):962-969.
［11］ TAKAI K,DRAIN AP,LAWSON DA,et al.Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers［J］.Genes Dev,2018,32(3-4):244-257.
［12］ DENNY WA,FLANAGAN JU.Inhibitors of discoidin domain receptor (DDR) kinases for cancer and inflammation［J］.Biomolecules,2021,11(11):1671.
［13］ MCDONELL LM,KERNOHAN KD,BOYCOTT KM,et al.Receptor tyrosine kinase mutations in developmental syndromes and cancer:two sides of the same coin［J］.Hum Mol Genet,2015,24(R1):R60-R66.
［14］ BUTTI R,DAS S,GUNASEKARAN VP,et al.Receptor tyrosine kinases (RTKs) in breast cancer:signaling,therapeutic implications and challenges［J］.Mol Cancer,2018,17(1):34.
［15］ NEBEN CL,LO M,JURA N,et al.Feedback regulation of RTK signaling in development［J］.Dev Biol,2019,447(1):71-89.
［16］ FANTAUZZO KA,SORIANO P.Receptor tyrosine kinase signaling:regulating neural crest development one phosphate at a time［J］.Curr Top Dev Biol,2015,111:135-182.
［17］ KROHN JB,HUTCHESON JD,MARTINEZ-MARTINEZ E,et al.Discoidin domain receptor-1 regulates calcific extracellular vesicle release in vascular smooth muscle cell fibrocalcific response via transforming growth factor-β signaling［J］.Arterioscler Thromb Vasc Biol,2016,36(3):525-533.
［18］ JUSKAITE V,CORCORAN DS,LEITINGER B.Collagen induces activation of DDR1 through lateral dimer association and phosphorylation between dimers［J］.Elife,2017,6:e25716.
［19］ SHRIVASTAVA A,RADZIEJEWSKI C,CAMPBELL E,et al.An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors［J］.Mol Cell,1997,1(1):25-34.
［20］ GAO H,CHAKRABORTY G,ZHANG Z,et al.Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling［J］.Cell,2016,166(1):47-62.
［21］ LEITINGER B.Molecular analysis of collagen binding by the human discoidin domain receptors,DDR1 and DDR2.Identification of collagen binding sites in DDR2［J］.J Biol Chem,2003,278(19):16761-16769.
［22］ BELLA J,HULMES DJ.Fibrillar collagens［J］.Subcell Biochem,2017,82:457-490.
［23］ POSEY KL,COUSTRY F,HECHT JT.Cartilage oligomeric matrix protein:COMPopathies and beyond［J］.Matrix Biol,2018,71-72:161-173.
［24］ PENG DH,UNGEWISS C,TONG P,et al.ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis［J］.Oncogene,2017,36(14):1925-1938.
［25］ VENNIN C,CHIN VT,WARREN SC,et al.Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression,sensitivity to chemotherapy,and metastasis［J］.Sci Transl Med,2017,9(384):eaai8504.
［26］ ZHENG X,LIU W,XIANG J,et al.Collagen Ⅰ promotes hepatocellular carcinoma cell proliferation by regulating integrin β1/FAK signaling pathway in nonalcoholic fatty liver［J］.Oncotarget,2017,8(56):95586-95595.
［27］ DEJMEK J,DIB K,JONSSON M,et al.Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion［J］.Int J Cancer,2003,103(3):344-351.
［28］ SHINTANI Y,FUKUMOTO Y,CHAIKA N,et al.Collagen Ⅰ-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1［J］.J Cell Biol,2008,180(6):1277-1289.
［29］ FERRI N,CARRAGHER NO,RAINES EW.Role of discoidin domain receptors 1 and 2 in human smooth muscle cell-mediated collagen remodeling:potential implications in atherosclerosis and lymphangioleiomyomatosis［J］.Am J Pathol,2004,164(5):1575-1585.
［30］ LU P,TAKAI K,WEAVER VM,et al.Extracellular matrix degradation and remodeling in development and disease［J］.Cold Spring Harb Perspect Biol,2011,3(12):a005058.
［31］ ROMAYOR I,BADIOLA I,OLASO E.Inhibition of DDR1 reduces invasive features of human A375 melanoma,HT29 colon carcinoma and SK-HEP hepatoma cells［J］.Cell Adh Migr,2020,14(1):69-81.
［32］ GIANCOTTI FG.Mechanisms governing metastatic dormancy and reactivation［J］.Cell,2013,155(4):750-764.
［33］ MALEKI EH,BAHRAMI AR,MATIN MM.Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance［J］.Genes Dis,2023,11(1):189-204.
［34］ PEREZ-GONZALEZ A,BEVANT K,BLANPAIN C.Cancer cell plasticity during tumor progression,metastasis and response to therapy［J］.Nat Cancer,2023,4(8):1063-1082.
［35］ DI MARTINO JS,NOBRE AR,MONDAL C,et al.A tumor-derived type Ⅲ collagen-rich ECM niche regulates tumor cell dormancy［J］.Nat Cancer,2022,3(1):90-107.
［36］ GUO Z,XIE Q,WU Y,et al.Aberrant expression of circular RNA DHPR facilitates tumor growth and metastasis by regulating the RASGEF1B/RAS/MAPK axis in hepatocellular carcinoma［J］.Cell Oncol (Dordr),2023,46(5):1333-1350.
［37］ ORGEL JPRO,MADHURAPANTULA RS.A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril［J］.Biochim Biophys Acta Mol Cell Res,2019,1866(11):118478.
［38］ TEWARI D,PATNI P,BISHAYEE A,et al.Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer:A novel therapeutic strategy［J］.Semin Cancer Biol,2022,80:1-17.
［39］ LIU J,XIAO Q,XIAO J,et al.Wnt/β-catenin signalling:function,biological mechanisms,and therapeutic opportunities［J］.Signal Transduct Target Ther,2022,7(1):3.
［40］ WANG J,JIANG YH,YANG PY,et al.Increased collagen type V α2 (COL5A2) in colorectal cancer is associated with poor prognosis and tumor progression［J］.Onco Targets Ther,2021,14:2991-3002.
［41］ GADIYA M,CHAKRABORTY G.Signaling by discoidin domain receptor 1 in cancer metastasis［J］.Cell Adh Migr,2018,12(4):315-323.
［42］ LU J,KISHORE U.C1 complex:an adaptable proteolytic module for complement and non-complement functions［J］.Front Immunol,2017,8:592.
［43］ BULLA R,TRIPODO C,RAMI D,et al.C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation［J］.Nat Commun,2016,7:10346.
［44］ LEE JH,POUDEL B,KI HH,et al.Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1［J］.Sci Rep,2018,8(1):4908.
［45］ VEHLOW A,CORDES N.DDR1 (discoidin domain receptor tyrosine kinase 1) drives glioblastoma therapy resistance by modulating autophagy［J］.Autophagy,2019,15(8):1487-1488.
［46］ HAYUNINGTYAS RA,HAN M,CHOI S,et al.The collagen structure of C1q induces wound healing by engaging discoidin domain receptor 2［J］.Mol Med,2021,27(1):125.
［47］ CANNING P,TAN L,CHU K,et al.Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type Ⅱ kinase inhibitors［J］.J Mol Biol,2014,426(13):2457-2470.
［48］ MONTENEGRO RC,HOWARTH A,CERONI A,et al.Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib［J］.Oncotarget,2020,11(5):535-549.
［49］ JEITANY M,LEROY C,TOSTI P,et al.Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer［J］.EMBO Mol Med,2018,10:e7918.
［50］ RAM R,LORENTE G,NIKOLICH K,et al.Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2［J］.J Neurooncol,2006,76(3):239-248.
［51］ TAO Y,WANG R,LAI Q,et al.Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma［J］.Mol Oncol,2019,13(9):1855-1873.
［52］ WANG Q,TANG B,SUN D,et al.Discovery of 4-cyclopropyl-3-(2-((1-cyclopropyl-1H-pyrazol-4-yl) amino) quinazolin-6-yl)-N-(3-(trifluoromethyl) phenyl) benzamides as potent discoidin domain receptor inhibitors for the treatment of idiopathic pulmonary fibrosis［J］.Acta Pharm Sin B,2022,12(4):1943-1962.
［53］ CHEN DH,LI Q.lncRNA and sorafenib resistance of hepatocellular carcinoma:New advances in molecular mechanisms and therapeutic targets［J］.Modern Oncology,2023,31(24):4633-4639.
［54］ REN HW,LIU JY,WU LX,et al.Safety and efficacy of camrelizumab combined with thalidomide for advanced hepatocellular carcinoma［J］.Modern Oncology,2022,30(12)：2201-2204.